These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20680271)

  • 61. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
    Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
    J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
    Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
    Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
    Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
    Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.
    Lum LG; Thakur A; Pray C; Kouttab N; Abedi M; Deol A; Colaiace WM; Rathore R
    Bone Marrow Transplant; 2014 Jan; 49(1):73-9. PubMed ID: 24056738
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
    Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
    Slavin S; Nagler A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.
    Olson JA; Zeiser R; Beilhack A; Goldman JJ; Negrin RS
    J Immunol; 2009 Sep; 183(5):3219-28. PubMed ID: 19657090
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
    Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
    Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Murray C; Gonin R; Ritz J
    Blood; 1994 Aug; 84(3):964-71. PubMed ID: 8043878
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expansion and activation of natural killer cells for cancer immunotherapy.
    Cho D; Campana D
    Korean J Lab Med; 2009 Apr; 29(2):89-96. PubMed ID: 19411773
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of peripheral NK cell counts with Helios
    Trojan K; Zhu L; Aly M; Weimer R; Bulut N; Morath C; Opelz G; Daniel V
    Clin Exp Immunol; 2017 Jun; 188(3):467-479. PubMed ID: 28194759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.